Literature DB >> 30121214

Optimization of diarylpentadienones as chemotherapeutics for prostate cancer.

Manee Patanapongpibul1, Changde Zhang2, Guanglin Chen1, Shanchun Guo2, Qiang Zhang2, Shilong Zheng2, Guangdi Wang2, Qiao-Hong Chen3.   

Abstract

Our earlier studies indicate that (1E,4E)-1,5-bis(1-alkyl-1H-imidazol-2-yl)penta-1,4-diene-3-ones and (1E,4E)-1,5-bis(1-alkyl-1H-benzo[d]imidazol-2-yl)penta-1,4-diene-3-ones exhibit up to 121-fold greater antiproliferative potency than curcumin in human prostate cancer cell models, but only 2-10 fold increase in mouse plasma concentrations. The present study aims to further optimize them as anti-prostate cancer agents with both good potency and bioavailability. (1E,4E)-1,5-Bis(1H-imidazol-2-yl)penta-1,4-diene-3-one, the potential metabolic product of (1E,4E)-1,5-bis(1-alkyl-1H-imidazol-2-yl)penta-1,4-diene-3-ones, was synthesized and evaluated for its anti-proliferative activity. The promising potency of 1,5-bis(1-alkyl-1H-imidazol-2-yl)penta-1,4-diene-3-ones was completely abolished by removing the 1-alkyl group, suggesting the critical role of an appropriate group on the N1 position. We then envisioned that N-aryl substitution to exclude the C-H bond on the carbon adjacent to the N1 position (α-H) may increase the metabolic stability. Consequently, seven (1E,4E)-1,5-bis(1-aryl-1H-imidazol-2-yl)penta-1,4-dien-3-ones and three (1E,4E)-1,5-bis(1-aryl-1H-benzo[d]imidazol-2-yl)penta-1,4-dien-3-ones, as well as three (1E,4E)-1,5-bis(1-aryl-1H-pyrrolo[3,2-b]pyridine-2-yl)penta-1,4-dien-3-ones, were synthesized through a three-step transformation, including N-arylation via Ullmann condensation, formylation, and Horner-Wadsworth-Emmons reaction. Six optimal (1E,4E)-1,5-bis(1-aryl-1H-imidazol-2-yl)penta-1,4-dien-3-ones exhibit 24- to 375-fold improved potency as compared with curcumin. Replacement of the imidazole with bulkier benzoimidazole and 4-azaindole results in a substantial decrease in the potency. (1E,4E)-1,5-Bis(1-(2-methoxyphenyl)-1H-imidazol-2-yl)penta-1,4-dien-3-one (17d) was established as an optimal compound with both superior potency and good bioavailability that is sufficient to provide the therapeutic efficacy necessary to suppress in vivo tumor growth.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiproliferative activity; Diarylpentadienone; Pharmacokinetic study; Prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 30121214      PMCID: PMC6219857          DOI: 10.1016/j.bmc.2018.08.018

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  15 in total

Review 1.  Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes.

Authors:  Bernard Meunier; Samuël P de Visser; Sason Shaik
Journal:  Chem Rev       Date:  2004-09       Impact factor: 60.622

2.  Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.

Authors:  Silke Hack; Babette Wörlein; Georg Höfner; Jörg Pabel; Klaus T Wanner
Journal:  Eur J Med Chem       Date:  2011-02-03       Impact factor: 6.514

3.  Structure-Activity Relationship and Pharmacokinetic Studies of 1,5-Diheteroarylpenta-1,4-dien-3-ones: A Class of Promising Curcumin-Based Anticancer Agents.

Authors:  Rubing Wang; Chengsheng Chen; Xiaojie Zhang; Changde Zhang; Qiu Zhong; Guanglin Chen; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  J Med Chem       Date:  2015-05-22       Impact factor: 7.446

4.  Mechanisms of the androgen receptor splicing in prostate cancer cells.

Authors:  L L Liu; N Xie; S Sun; S Plymate; E Mostaghel; X Dong
Journal:  Oncogene       Date:  2013-07-15       Impact factor: 9.867

Review 5.  Curcumin-based anti-prostate cancer agents.

Authors:  Qiao-Hong Chen
Journal:  Anticancer Agents Med Chem       Date:  2015       Impact factor: 2.505

Review 6.  Bioavailability of curcumin: problems and promises.

Authors:  Preetha Anand; Ajaikumar B Kunnumakkara; Robert A Newman; Bharat B Aggarwal
Journal:  Mol Pharm       Date:  2007-11-14       Impact factor: 4.939

7.  Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells.

Authors:  T Dorai; N Gehani; A Katz
Journal:  Prostate Cancer Prostatic Dis       Date:  2000-08       Impact factor: 5.554

8.  Chemopreventive potential of curcumin in prostate cancer.

Authors:  Marie-Hélène Teiten; François Gaascht; Serge Eifes; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2009-10-06       Impact factor: 5.523

9.  Design, synthesis, and evaluation of novel heteroaromatic analogs of curcumin as anti-cancer agents.

Authors:  Nawras Samaan; Qiu Zhong; Jayjoel Fernandez; Guanglin Chen; Ali M Hussain; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Eur J Med Chem       Date:  2014-01-29       Impact factor: 6.514

Review 10.  Eliminating the heart from the curcumin molecule: monocarbonyl curcumin mimics (MACs).

Authors:  Dinesh Shetty; Yong Joon Kim; Hyunsuk Shim; James P Snyder
Journal:  Molecules       Date:  2014-12-24       Impact factor: 4.411

View more
  1 in total

1.  Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties.

Authors:  Aladdin M Srour; Siva S Panda; Ahmed Mostafa; Walid Fayad; May A El-Manawaty; Ahmed A F Soliman; Yassmin Moatasim; Ahmed El Taweel; Mohamed F Abdelhameed; Mohamed S Bekheit; Mohamed A Ali; Adel S Girgis
Journal:  Bioorg Chem       Date:  2021-11-04       Impact factor: 5.275

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.